Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
3.2 Clinical medicine, Expert, Latvian Council of Science
6 Apr 2023 → 5 Apr 2026
3.2 Clinical medicine, Expert, Latvian Council of Science
26 May 2020 → 25 May 2023
Field of Science
- 3.2 Clinical medicine
Fingerprint
Dive into the research topics where Iveta Kudaba is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Active
-
MicroRNA expression as a predictive biomarker for locally advanced breast cancer to evaluate the efficacy of systemic treatment
Liepiņa, E. (Project leader), Kudaba, I. (Supervisor) & Miklaševičs, E. (Supervisor)
1/10/20 → 30/09/25
Project: PhD projects
-
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
de Castro, G. (Corresponding Author), Kudaba, I., Wu, Y.-L., Lopes, G., Kowalski, D. M., Turna, H. Z., Caglevic, C., Zhang, L., Karaszewska, B., Laktionov, K. K., Srimuninnimit, V., Bondarenko, I., Kubota, K., Mukherjee, R., Lin, J., Souza, F., Mok, T. S. K. & Cho, B. C., Apr 2023, In: Journal of Clinical Oncology. 41, 11, p. 1986-1991Research output: Contribution to journal › Article › peer-review
Open Access92 Citations (Scopus) -
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Lee, K. W. (Corresponding Author), Van Cutsem, E., Bang, Y. J., Fuchs, C. S., Kudaba, I., Garrido, M., Chung, H. C., Lee, J., Castro, H. R., Chao, J., Wainberg, Z. A., Cao, Z. A., Aurora-Garg, D., Kobie, J., Cristescu, R., Bhagia, P., Shah, S., Tabernero, J., Shitara, K. & Wyrwicz, L., 15 Aug 2022, In: Clinical Cancer Research. 28, 16, p. 3489-3498 10 p.Research output: Contribution to journal › Article › peer-review
39 Citations (Scopus) -
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
Wainberg, Z., Shitara, K., Van Cutsem, E., Wyrwicz, L., Lee, K., Kudaba, I., Garrido, M., Chung, H., Lee, J., Castro-Salguero, H., Mansoor, W., Braghiroli, M., Karaseva, N., Goekkurt, E., Satake, H., Chao, J., Kher, U., Shah, S., Bhagia, P. & Tabernero, J., 1 Feb 2022, In: Journal of Clinical Oncology. 40, 4, Suppl., 243.Research output: Contribution to journal › Meeting Abstract › peer-review
Open Access -
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer
Dómine Gómez, M., Csőszi, T., Jaal, J., Kudaba, I., Nikolov, K., Radosavljevic, D., Xiao, J., Horton, J. K., Malik, R. K. & Subramanian, J. (Corresponding Author), 1 Oct 2021, In: International Journal of Cancer. 149, 7, p. 1463-1472 10 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile12 Citations (Scopus)16 Downloads (Pure) -
Keynote-042 5-year Survival Update: Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated, Pd-L1positive, Locally Advanced Or Metastatic Non-small-cell Lung Cancer
de Castro, G., Kudaba, I., Wu, Y., Lopes, G., Kowalski, D., Turna, H., Caglevic, C., Zhang, L., Karaszewska, B., Laktionov, K., Srimuninnimit, V., Bondarenko, I., Kubota, K., Mukherjee, R., Lin, J., Souza, F., Mok, T. & Cho, B., Nov 2021, In: Journal for ImmunoTherapy of Cancer. 9, Suppl.2, p. A390 363.Research output: Contribution to journal › Meeting Abstract › peer-review
Open Access
Activities
-
GI CANCER MASTERCLASS
Kudaba, I. (Participant)
2 Oct 2022 → 4 Oct 2022Activity: Participating in or organising an event types › Participating in a conference, workshop, ...
-
International Association for the Study of Lung Cancer - 2022 World Conference on Lung Cancer
Kudaba, I. (Participant)
6 Aug 2022 → 9 Aug 2022Activity: Participating in or organising an event types › Participating in a conference, workshop, ...
-
American Society of Clinical Oncology (ASCO) Annual Meeting 2022
Kudaba, I. (Participant)
3 Jun 2022 → 7 Jun 2022Activity: Participating in or organising an event types › Participating in a conference, workshop, ...
-
ESMO BREAST CANCER 2022
Kudaba, I. (Participant)
3 May 2022 → 5 May 2022Activity: Participating in or organising an event types › Participating in a conference, workshop, ...
-
RSU Research week 2021: Knowledge for Use in Practice (Event)
Kudaba, I. (Reviewer of conference paper)
24 Mar 2021Activity: Publication peer-review and editorial work types › Publication Peer-review